Curantil® N 75 (Curantyl® N 75)

Has a retarding effect on the aggregation of platelets, improves microcirculation, has a mild vasodilating action.

Dipiridamol dilates the arterioles in the coronary blood flow system, with increasing doses - also in other parts of the circulatory system. However, unlike organic nitrates and calcium antagonists, the expansion of larger coronary vessels does not occur. The vasodilating effect of dipyridamole is due to two different mechanisms of inhibition.

Suppression of adenosine capture. In vivo adenosine is found at a concentration of approximately 0.15-0.20 μmol. This level is maintained due to the dynamic balance between ejection and re-capture. Dipyridamole inhibits the capture of adenosine by endothelial cells, erythrocytes and platelets. After the introduction of dipyridamole, an increase in the concentration of adenosine in the blood and an increase in adenosine-mediated vasodilatation are found. In higher doses, inhibition of platelet aggregation caused by adenosine occurs, and the tendency to thrombogenesis decreases.

Inhibition of phosphodiesterase. The disintegration of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), which inhibit platelet aggregation, occurs in platelets under the action of the corresponding phosphodiesterases.In high concentrations dipyridamole oppresses both phosphodiesterases, in therapeutic concentrations in the blood - only cGMP phosphodiesterase. As a result of stimulation of corresponding cycles, the power of cAMP synthesis increases.